Analysts expect INSYS Therapeutics, Inc. (NASDAQ:INSY) to report $-0.33 EPS on March, 14.They anticipate $0.10 EPS change or 43.48% from last quarter’s $-0.23 EPS. After having $-0.40 EPS previously, INSYS Therapeutics, Inc.’s analysts see -17.50% EPS growth. The stock decreased 2.85% or $0.1259 during the last trading session, reaching $4.2841. About 969,165 shares traded or 29.30% up from the average. INSYS Therapeutics, Inc. (NASDAQ:INSY) has declined 12.29% since February 11, 2018 and is downtrending. It has underperformed by 12.29% the S&P500. Some Historical INSY News: 18/04/2018 – INSYS Therapeutics to Advance Clinical Research of Dronabinol lnhalation Using Novel Breath-Actuated Device; 19/04/2018 – GW PHARMACEUTICALS AND U.S. SUBSIDIARY GREENWICH BIOSCIENCES ANNOUNCES THE UNANIMOUS POSITIVE RESULT OF FDA ADVISORY COMMITTEE MEETING FOR FIRST PLANT-BASED PHARMACEUTICAL CANNABIDIOL TREATMENT; 30/05/2018 – CORRECT: NJ AG SAYS EX-SALES REP FOR INSYS PLEADS GUILTY; 08/05/2018 – INSYS – CO’S RESPONSIBILITIES WILL INCLUDE SUPPLYING SUBSYS TO LUNATUS, WHOSE RESPONSIBILITIES WILL INCLUDE OBTAINING APPROVALS TO COMMERCIALIZE SUBSYS; 08/05/2018 – INSYS, LUNATUS TO COMMERCIALIZE SUBSYS SPRAY IN MIDDLE EAST; 22/05/2018 – Insys Therapeutics Will Continue to Work With FDA to Discuss Path Forward for Buprenorphine Product; 08/05/2018 – INSYS 1Q ADJ EPS 19C, EST. LOSS/SHR 17C; 15/05/2018 – lnsys sees no change in estimated litigation costs; 27/04/2018 – INSYS Therapeutics Initiates Phase 2 Clinical Trial of Cannabidiol (CBD) for Treatment of Prader-Willi Syndrome; 14/05/2018 – EX-INSYS WHISTLE-BLOWER SUIT OVER KICKBACKS GETS U.S. BACKING
HANG LUNG PROPERTIES LTD ORDINARY SHARES (OTCMKTS:HLPPF) had an increase of 37.37% in short interest. HLPPF’s SI was 3.51M shares in February as released by FINRA. Its up 37.37% from 2.56M shares previously. With 33,100 avg volume, 106 days are for HANG LUNG PROPERTIES LTD ORDINARY SHARES (OTCMKTS:HLPPF)’s short sellers to cover HLPPF’s short positions. It closed at $2.04 lastly. It is down 0.00% since February 11, 2018 and is . It has by 0.00% the S&P500.
Hang Lung Properties Limited, an investment holding company, engages in the property investment, development, and management activities in Hong Kong and Mainland China. The company has market cap of $10.08 billion. The companyÂ’s portfolio includes mall/commercial, office, residential, serviced apartments, industrial/office, and car park properties. It has a 8.03 P/E ratio. It is also involved in property leasing; apartment operating and management; project management; and property agency activities, as well as provides management and financial services.
Another recent and important Hang Lung Properties Limited (OTCMKTS:HLPPF) news was published by Investorplace.com which published an article titled: “The 3 Best Mutual Funds to Buy Emerging Markets – Investorplace.com” on July 26, 2016.
Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company has market cap of $318.18 million. The firm markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant cancer patients in the United States. It currently has negative earnings. The Company’s lead product candidate is SYNDROS, an orally administered liquid formulation of dronabinol for treating CINV and anorexia associated with weight loss in patients with AIDS.
Among 2 analysts covering Insys Therapeutics (NASDAQ:INSY), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Insys Therapeutics had 2 analyst reports since December 19, 2018 according to SRatingsIntel. The company was reinitiated on Wednesday, December 19 by Janney Capital.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.